Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings

A veteran in cell therapy and oncology commercialisation

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)

Aurobindo Pharma bags USFDA nod for Glycerol Phenylbutyrate Oral Liquid

The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics

Novartis CEO Vas Narasimhan joins Anthropic board

Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery

Aurobindo Pharma wins USFDA nod for rare disease drug set for immediate launch

Aurigene, Alveus advance obesity pipeline with ALV-200 candidate nomination

The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities

India Pharma 2026 concludes with strong call for funding, infrastructure and speed to power innovation

The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions

Oxford-ZEISS advances breakthrough live-cell imaging platform for next-gen drug discovery

The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners

FDA clears Travere’s FILSPARI for expanded use in rare kidney disease